H. Lundbeck aktie (HLUN B) | Pressmeddelande

Lundbeck Annual Report 2024

Cision • Idag 07:46

Lundbeck reached record revenue of DKK 22 billion in 2024 with accelerated growth for strategic brands (+21% CER)

Cision • Idag 07:23

Lundbeck announces changes to the Board of Directors

Cision • Igår 17:10

Lundbeck announces positive results from 12-month Open-Label Extension (OLE) of the PACIFIC trial evaluating bexicaserin in participants with Developmental and Epileptic Encephalopathies

Bexicaserin achieved an overall median seizure reduction of 59.

Cision • 30 Jan 09:00

Lundbeck announces FDA plans to host an Advisory Committee meeting on the sNDA for brexpiprazole in combination with sertraline for the treatment of adults with PTSD

Lundbeck announces FDA plans to host an Advisory Committee meeting on the sNDA for brexpiprazole in combination with sertraline for the trea...

Cision • 09 Jan 14:07

Lundbeck highlights commitment to the rare epilepsy community at American Epilepsy Society (AES) Annual Meeting with data presentations

Longboard Pharmaceuticals, now a wholly owned subsidiary of Lundbeck, presents scientific data in multiple poster presentations showcasing t...

Cision • 05 Dec 2024 13:00

Efficacy of Vyepti highlighted by new clinical trial results in severe migraine

New results from the RESOLUTION trial demonstrate the efficacy of Vyepti® (eptinezumab) on top of patient education for patients severely im...

Cision • 03 Dec 2024 08:00

Lundbeck completes acquisition of Longboard

Cision • 02 Dec 2024 15:08

Lundbeck announces expiration of Longboard tender offer and that all tender offer conditions are fulfilled

Cision • 28 Nov 2024 07:56

Lundbeck initiates a phase III trial with amlenetug for the treatment of Multiple System Atrophy

MASCOT, a global phase III randomized, double-blind, placebo-controlled trial, will assess the efficacy and safety of amlenetug in the treat...

Cision • 27 Nov 2024 08:00

Accelerated growth for strategic brands (+21% CER) drives revenue up 13% CER in the first nine months of 2024

Cision • 13 Nov 2024 07:29

Lundbeck announces positive results from phase III pivotal trial (SUNRISE) of Vyepti® (eptinezumab) in migraine prevention

Cision • 31 Oct 2024 12:44

Capital Markets Event 2024: Lundbeck to showcase progress on Focused Innovator Strategy driving sustainable long-term growth

Cision • 23 Oct 2024 09:01

Lundbeck to acquire Longboard Pharmaceuticals in a strategic deal, significantly enhancing its neuroscience pipeline

Cision • 14 Oct 2024 12:30

Lundbeck initiates clinical trial in immunology for Lu AG22515 in Thyroid Eye Disease

H. Lundbeck A/S (Lundbeck) today announced taking one further step in developing treatments for indications in the neuroimmunology and neuro...

Cision • 03 Oct 2024 09:00

Lundbeck presents results from two studies in Multiple System Atrophy at International Congress of Parkinson's Disease and Movement Disorders

Lundbeck advances its commitment to addressing the unmet needs of Multiple System Atrophy (MSA) with the TALISMAN study, adding to the encou...

Cision • 27 Sep 2024 14:00

Lundbeck and Iambic Therapeutics announce strategic partnership to leverage AI for drug discovery

Lundbeck partners with Iambic to utilize its AI-powered drug discovery platform to accelerate research and therapeutic innovation for neurol...

Cision • 26 Sep 2024 12:00

Lundbeck raised financial guidance following strong growth (+19% CER) from strategic brands, on path towards becoming a Focused Innovator

Cision • 20 Aug 2024 09:09

Lundbeck raises financial guidance for 2024

Cision • 20 Aug 2024 08:53

Lundbeck and Takeda modify the collaboration agreement for Trintellix in the U.S.

In accordance with Lundbeck’s Focused Innovator strategy, the collaboration with Takeda for the U.

Cision • 31 Jul 2024 08:00

Lundbeck and Otsuka announce FDA acceptance of sNDA filing for brexpiprazole in combination with sertraline for the treatment of adults with post-traumatic stress disorder (PTSD)

Lundbeck and Otsuka announce FDA acceptance of sNDA filing for brexpiprazole in combination with sertraline for the treatment of adults with...

Cision • 25 Jun 2024 07:59

Lundbeck broadens focus on neurohormonal dysfunctions with new Cushing’s disease trial

Lundbeck is exploring a new area in neurohormonal dysfunctions by initiating a phase II trial using Lu AG13909 as a potential treatment for ...

Cision • 19 Jun 2024 08:30

Lundbeck presents innovative first in human trial design of Lu AG13909 for potential treatment of congenital adrenal hyperplasia

Lundbeck is to showcase innovative trial design at ENDO 2024 of the first in human trial of Lu AG13909 for congenital adrenal hyperplasia (C...

Cision • 03 Jun 2024 14:00

Lundbeck grows strategic brands by +17% CER reaching total revenue of DKK 5.3 billion in the first quarter of 2024

Lundbeck grows strategic brands by +17% CER reaching total revenue of DKK 5.

Cision • 15 May 2024 07:31

Maria Alfaiate appointed new Executive Vice President Commercial and Corporate Strategy at Lundbeck

H. Lundbeck A/S (Lundbeck) today announced the appointment of Maria Alfaiate to the newly established role of EVP, Commercial and Corporate ...

Cision • 13 May 2024 09:00

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD

Cision • 09 Apr 2024 08:00

Abilify Maintena[®] 960 mg (aripiprazole) approved in the EU as the first once-every-two-months long-acting injectable for the maintenance treatment of schizophrenia

Aripiprazole’s new long-acting injectable (LAI) formulation enables continuous exposure to medication for two months[1.

Cision • 27 Mar 2024 08:00

Lundbeck held its Annual General Meeting on 20 March 2024 at the company’s registered office

Cision • 20 Mar 2024 13:33

Lundbeck’s potential first-in-class therapy for migraine prevention enters advanced clinical stage

PROCEED, a clinical phase IIb dose-finding trial will assess the efficacy and safety of subcutaneously administered Lu AG09222 in migraine p...

Cision • 15 Mar 2024 09:00

Lundbeck presents encouraging results from the Lu AF82422 trial for Multiple System Atrophy at the international AD/PD 2024 conference on neurodegenerative disorders

The AMULET trial strengthens the case for Lundbeck's Lu AF82422, as initial clinical data suggests that the anti-alpha-synuclein monoclonal ...

Cision • 05 Mar 2024 09:00

Notice of Annual General Meeting

Cision • 23 Feb 2024 11:00

Lundbeck announces changes to Executive Management

Cision • 23 Feb 2024 08:59

Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties

Transactions with shares and linked securities in H.

Cision • 16 Feb 2024 11:45

Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties

Transactions with shares and linked securities in H.

Cision • 07 Feb 2024 15:23

Lundbeck Annual Report 2023

Cision • 07 Feb 2024 07:33

Lundbeck reached record revenue of DKK 20 billion in 2023 with strong growth momentum set to continue in 2024

Cision • 07 Feb 2024 07:29

Dianne Hol appointed new Executive Vice President People & Organization at Lundbeck

H. Lundbeck A/S (Lundbeck) today announced the appointment of Dianne Hol to the role of EVP, People & Organization.

Cision • 05 Feb 2024 15:00

Lundbeck announces supportive phase II results with Lu AF82422 in the treatment of Multiple System Atrophy from the AMULET trial

Cision • 31 Jan 2024 14:06

Aripiprazole once-every-two-months long-acting injectable recommended for approval in the EU by the CHMP for the maintenance treatment of schizophrenia in adult patients stabilised with aripiprazole

Subject to final approval by the European Commission, the drug will be the first once-every-two-months long-acting injectable (LAI) antipsyc...

Cision • 29 Jan 2024 09:00

Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties

Transactions with shares and linked securities in H.

Cision • 20 Dec 2023 13:27

Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties

Transactions with shares and linked securities in H.

Cision • 04 Dec 2023 12:07

Lundbeck R&D Event to showcase innovative pipeline

H. Lundbeck A/S (Lundbeck) is hosting an R&D Event in London today, providing analysts and investors with an update on the progress of its R...

Cision • 30 Nov 2023 08:59

Lundbeck's revenue in the first nine months of 2023 climbed to DKK 15 billion

Cision • 08 Nov 2023 07:30

Lundbeck presents clinical advances in migraine prevention with positive trial results at international headache congress

The HOPE trial, together with a clinical mechanism of action study, strengthens the case for Lundbeck's Lu AG09222, as additional data highl...

Cision • 14 Sep 2023 09:02

Lundbeck and Otsuka announce topline results from two phase III trials of brexpiprazole as combination therapy with sertraline for the treatment of Post-Traumatic Stress Disorder in adults

Lundbeck and Otsuka announce topline results from two phase III trials of brexpiprazole as combination therapy with sertraline for the treat...

Cision • 07 Sep 2023 10:59

Lundbeck announces changes to Executive Management

Cision • 18 Aug 2023 13:21

Lundbeck’s revenue increased by 13% (+10% CER) to DKK 10 billion in the first six months of 2023

Cision • 16 Aug 2023 07:28

The Board of Directors initiates CEO succession

Cision • 26 Jun 2023 09:33

Long-term benefits of Vyepti[®] confirmed by new data presented at the annual meeting of the American Headache Society

An extension phase of the DELIVER study with Vyepti[®] (eptinezumab) demonstrated long-lasting migraine preventive effects with treatment fo...

Cision • 16 Jun 2023 08:55

Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties

Transactions with shares and linked securities in H.

Cision • 15 May 2023 07:53

Lundbeck and Otsuka announce U.S. Food and Drug Administration (FDA) approval of sNDA for Rexulti® (brexpiprazole) for the treatment of agitation associated with dementia due to Alzheimer’s Disease

Lundbeck and Otsuka announce U.S. Food and Drug Administration (FDA) approval of sNDA for Rexulti® (brexpiprazole) for the treatment of agit...

Cision • 11 May 2023 05:25

Lundbeck’s sales increased by 15% (+11% at constant exchange rates) to DKK 5 billion in the first quarter of 2023

Cision • 10 May 2023 07:32

Lundbeck announces positive phase II Proof of Concept results with Lu AG09222 in migraine prevention

Cision • 19 Apr 2023 15:43

Lundbeck held its Annual General Meeting on 21 March 2023 at the company’s registered office

Cision • 21 Mar 2023 13:27

Notice of Annual General Meeting

Cision • 22 Feb 2023 10:00

Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties

Transactions with shares and linked securities in H.

Cision • 14 Feb 2023 16:32

Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties

Transactions with shares and linked securities in H.

Cision • 10 Feb 2023 15:13

Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties

Transactions with shares and linked securities in H.

Cision • 08 Feb 2023 14:51

Lundbeck Annual Report 2022

Cision • 08 Feb 2023 08:30

Lundbeck delivers record revenue of DKK 18.2 billion and grows 12% in 2022

Cision • 07 Feb 2023 12:35

Lundbeck announces financial guidance for 2023 and mid-term financial targets that build on very strong 2022 performance

Cision • 07 Feb 2023 12:24

Thomas Gibbs to join Lundbeck as Executive Vice President and Head of Lundbeck in the United States

Cision • 12 Jan 2023 14:58

Lundbeck announces FDA acceptance and priority review of sNDA for brexpiprazole for the treatment of agitation associated with Alzheimer’s dementia

Lundbeck announces FDA acceptance and priority review of sNDA for brexpiprazole for the treatment of agitation associated with Alzheimer’s d...

Cision • 07 Jan 2023 15:31

Lundbeck’s sales increased by 11% (+6% in local currencies) to DKK 13.6 billion in the first nine months of 2022

Lundbeck’s sales increased by 11% (+6% in local currencies) to DKK 13.

Cision • 09 Nov 2022 07:30

Lundbeck raises financial guidance range for the full year 2022

Cision • 08 Nov 2022 13:38

New study presented at ECNP 2022 finds that vortioxetine improves depressive symptoms and cognitive function in patients with Major Depressive Disorder and co-morbid dementia

New study presented at ECNP 2022 finds that vortioxetine improves depressive symptoms and cognitive function in patients with Major Depressi...

Cision • 18 Oct 2022 08:59

Lundbeck’s sales increased by +7% (+3% in local currencies) to DKK 8,847 million in the first half of 2022

Cision • 17 Aug 2022 07:30

Lundbeck raises financial guidance range for the full year 2022

Cision • 09 Aug 2022 15:46

Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties

Transactions with shares and linked securities in H.

Cision • 12 Jul 2022 14:46

Lundbeck and Otsuka Pharmaceutical announce positive results showing reduced agitation in patients with Alzheimer’s dementia treated with brexpiprazole

Lundbeck and Otsuka Pharmaceutical announce positive results showing reduced agitation in patients with Alzheimer’s dementia treated with br...

Cision • 27 Jun 2022 02:00

Results from the DELIVER study with Vyepti® has been published in a top-ranking medical journal

The primary and key secondary results on Vyepti® (eptinezumab) from the DELIVER study in patients with migraine and prior preventive treatme...

Cision • 16 Jun 2022 09:00

New share structure and official listing of new share classes, and total number of voting rights and share capital

Cision • 08 Jun 2022 13:26

Lundbeck Extraordinary General Meeting on June 8, 2022 at the company’s registered office

Cision • 08 Jun 2022 10:44

Lundbeck publishes Listing Document relating to the new share structure

Cision • 20 May 2022 10:08

Notice of Extraordinary General Meeting

Cision • 16 May 2022 13:36

Focus on strategic brands continues to ensure solid operational performance in Q1 2022

Cision • 11 May 2022 07:27

Vortioxetine demonstrates advantage on daily and social functioning vs. desvenlafaxine in a large head-to-head study

Vortioxetine demonstrates advantage on daily and social functioning vs.

Cision • 11 Apr 2022 09:00

Joerg Hornstein to join Lundbeck as Chief Financial Officer and Head of Corporate Functions

Cision • 08 Apr 2022 13:36

Lundbeck held its Annual General Meeting on 23 March 2022 at the company’s registered office

Cision • 23 Mar 2022 13:49

Notice of Annual General Meeting

Cision • 28 Feb 2022 12:01

Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties

Transactions with shares and linked securities in H.

Cision • 11 Feb 2022 16:50

Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties

Transactions with shares and linked securities in H.

Cision • 10 Feb 2022 15:00

Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties

Transactions with shares and linked securities in H.

Cision • 09 Feb 2022 14:39

Lundbeck Annual Report 2021

Cision • 09 Feb 2022 07:40

Strong operational performance with continued solid growth from strategic brands in Q4 2021

Cision • 09 Feb 2022 07:31

Lundbeck proposes a new share structure with A-shares and B-shares to increase financial capacity to fund future growth opportunities

Cision • 09 Feb 2022 07:12

Vyepti[®] (eptinezumab) approved by the EU Commission for the preventive treatment of migraine in adults

Cision • 24 Jan 2022 17:50

Lundbeck announced the start of a phase II clinical study to assess Lu AG09222 for migraine prevention

The HOPE study, a clinical phase II study, will assess the efficacy, safety, and tolerability of Lu AG09222 in migraine prevention.

Cision • 15 Nov 2021 09:01

Vyepti[®] recommended for approval in the EU by CHMP for the preventive treatment of migraine in adults

Cision • 12 Nov 2021 13:25

Lundbeck continues solid operational performance with strong growth from strategic brands in Q3 2021

Cision • 10 Nov 2021 07:39

Lundbeck launches a phase II study for potential new treatment of multiple system atrophy

Lu AF82422 represents a novel approach for potential treatment of multiple system atrophy (MSA), which currently represents a high and urgen...

Cision • 08 Nov 2021 09:00

Lundbeck reports positive results for Vyepti[®] (eptinezumab) from the DELIVER study in patients with migraine and prior preventive treatment failures

· The DELIVER study met its primary endpoint of change from baseline in the number of monthly migraine days (MMDs), while significantly m...

Cision • 01 Nov 2021 09:00

Lundbeck receives exclusive rights to APB-A1, an innovative phase I-ready bio-therapeutic for the treatment of neuroimmune diseases from AprilBio

· APB-A1 targets the clinically validated CD40L/CD40 biology which is central to a wide range of attractive neuroimmune indications · A...

Cision • 14 Oct 2021 09:00

U.S. court issues decision in Trintellix patent litigation upholding active ingredient patent

Cision • 01 Oct 2021 08:30

Lundbeck continues to deliver solid growth for strategic brands and the financial guidance range has been updated

Cision • 18 Aug 2021 07:28

Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties

Transactions with shares and linked securities in H.

Cision • 26 May 2021 10:17

Lundbeck delivers a solid EBIT of DKK 882 million and Vyepti is off to a good start

Cision • 11 May 2021 07:33

Börskollen

För dig med koll på börsen

Pressmeddelanden från H. Lundbeck

Lundbeck Annual Report 2024

Lundbeck reached record revenue of DKK 22 billion in 2024 with accelerated growth for strategic brands (+21% CER)

Lundbeck announces changes to the Board of Directors

Lundbeck announces positive results from 12-month Open-Label Extension (OLE) of the PACIFIC trial evaluating bexicaserin in participants with Developmental and Epileptic Encephalopathies

Lundbeck announces FDA plans to host an Advisory Committee meeting on the sNDA for brexpiprazole in combination with sertraline for the treatment of adults with PTSD

Lundbeck highlights commitment to the rare epilepsy community at American Epilepsy Society (AES) Annual Meeting with data presentations

Efficacy of Vyepti highlighted by new clinical trial results in severe migraine

Lundbeck completes acquisition of Longboard

Lundbeck announces expiration of Longboard tender offer and that all tender offer conditions are fulfilled

Lundbeck initiates a phase III trial with amlenetug for the treatment of Multiple System Atrophy

Accelerated growth for strategic brands (+21% CER) drives revenue up 13% CER in the first nine months of 2024

Lundbeck announces positive results from phase III pivotal trial (SUNRISE) of Vyepti® (eptinezumab) in migraine prevention

Capital Markets Event 2024: Lundbeck to showcase progress on Focused Innovator Strategy driving sustainable long-term growth

Lundbeck to acquire Longboard Pharmaceuticals in a strategic deal, significantly enhancing its neuroscience pipeline

Lundbeck initiates clinical trial in immunology for Lu AG22515 in Thyroid Eye Disease

Lundbeck presents results from two studies in Multiple System Atrophy at International Congress of Parkinson's Disease and Movement Disorders

Lundbeck and Iambic Therapeutics announce strategic partnership to leverage AI for drug discovery

Lundbeck raised financial guidance following strong growth (+19% CER) from strategic brands, on path towards becoming a Focused Innovator

Lundbeck raises financial guidance for 2024

Lundbeck and Takeda modify the collaboration agreement for Trintellix in the U.S.

Lundbeck and Otsuka announce FDA acceptance of sNDA filing for brexpiprazole in combination with sertraline for the treatment of adults with post-traumatic stress disorder (PTSD)

Lundbeck broadens focus on neurohormonal dysfunctions with new Cushing’s disease trial

Lundbeck presents innovative first in human trial design of Lu AG13909 for potential treatment of congenital adrenal hyperplasia

Lundbeck grows strategic brands by +17% CER reaching total revenue of DKK 5.3 billion in the first quarter of 2024

Maria Alfaiate appointed new Executive Vice President Commercial and Corporate Strategy at Lundbeck

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD

Abilify Maintena[®] 960 mg (aripiprazole) approved in the EU as the first once-every-two-months long-acting injectable for the maintenance treatment of schizophrenia

Lundbeck held its Annual General Meeting on 20 March 2024 at the company’s registered office

Lundbeck’s potential first-in-class therapy for migraine prevention enters advanced clinical stage

Lundbeck presents encouraging results from the Lu AF82422 trial for Multiple System Atrophy at the international AD/PD 2024 conference on neurodegenerative disorders

Notice of Annual General Meeting

Lundbeck announces changes to Executive Management

Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties

Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties

Lundbeck Annual Report 2023

Lundbeck reached record revenue of DKK 20 billion in 2023 with strong growth momentum set to continue in 2024

Dianne Hol appointed new Executive Vice President People & Organization at Lundbeck

Lundbeck announces supportive phase II results with Lu AF82422 in the treatment of Multiple System Atrophy from the AMULET trial

Aripiprazole once-every-two-months long-acting injectable recommended for approval in the EU by the CHMP for the maintenance treatment of schizophrenia in adult patients stabilised with aripiprazole

Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties

Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties

Lundbeck R&D Event to showcase innovative pipeline

Lundbeck's revenue in the first nine months of 2023 climbed to DKK 15 billion

Lundbeck presents clinical advances in migraine prevention with positive trial results at international headache congress

Lundbeck and Otsuka announce topline results from two phase III trials of brexpiprazole as combination therapy with sertraline for the treatment of Post-Traumatic Stress Disorder in adults

Lundbeck announces changes to Executive Management

Lundbeck’s revenue increased by 13% (+10% CER) to DKK 10 billion in the first six months of 2023

The Board of Directors initiates CEO succession

Long-term benefits of Vyepti[®] confirmed by new data presented at the annual meeting of the American Headache Society

Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties

Lundbeck and Otsuka announce U.S. Food and Drug Administration (FDA) approval of sNDA for Rexulti® (brexpiprazole) for the treatment of agitation associated with dementia due to Alzheimer’s Disease

Lundbeck’s sales increased by 15% (+11% at constant exchange rates) to DKK 5 billion in the first quarter of 2023

Lundbeck announces positive phase II Proof of Concept results with Lu AG09222 in migraine prevention

Lundbeck held its Annual General Meeting on 21 March 2023 at the company’s registered office

Notice of Annual General Meeting

Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties

Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties

Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties

Lundbeck Annual Report 2022

Lundbeck delivers record revenue of DKK 18.2 billion and grows 12% in 2022

Lundbeck announces financial guidance for 2023 and mid-term financial targets that build on very strong 2022 performance

Thomas Gibbs to join Lundbeck as Executive Vice President and Head of Lundbeck in the United States

Lundbeck announces FDA acceptance and priority review of sNDA for brexpiprazole for the treatment of agitation associated with Alzheimer’s dementia

Lundbeck’s sales increased by 11% (+6% in local currencies) to DKK 13.6 billion in the first nine months of 2022

Lundbeck raises financial guidance range for the full year 2022

New study presented at ECNP 2022 finds that vortioxetine improves depressive symptoms and cognitive function in patients with Major Depressive Disorder and co-morbid dementia

Lundbeck’s sales increased by +7% (+3% in local currencies) to DKK 8,847 million in the first half of 2022

Lundbeck raises financial guidance range for the full year 2022

Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties

Lundbeck and Otsuka Pharmaceutical announce positive results showing reduced agitation in patients with Alzheimer’s dementia treated with brexpiprazole

Results from the DELIVER study with Vyepti® has been published in a top-ranking medical journal

New share structure and official listing of new share classes, and total number of voting rights and share capital

Lundbeck Extraordinary General Meeting on June 8, 2022 at the company’s registered office

Lundbeck publishes Listing Document relating to the new share structure

Notice of Extraordinary General Meeting

Focus on strategic brands continues to ensure solid operational performance in Q1 2022

Vortioxetine demonstrates advantage on daily and social functioning vs. desvenlafaxine in a large head-to-head study